Argus
Pull evidence.
Query 15+ bioinformatics databases for a gene target — expression, variants, constraint, pathways — and materialize one normalized evidence packet.
- Signal
- Evidence
- Amenability
- Design
- Review
RINAE.AI · The AI lab for RNA medicines
We exist to make genetic medicines. At scale.
An automated platform for genetic disease treatments — from genetic signal to drug design in one connected workflow.
The Problem
Rare disease is not rare. Treatments are.
Conventional drug development is unrepeatable, unautomated, and too expensive. Consequently, most genetic diseases can never be treated — even though the technology exists.
400M
People living with rare disease
A population the size of a continent, spread across thousands of conditions.
90%
Have no approved treatment
The overwhelming majority of genetic diseases have nothing on the shelf.
10%
Chance any drug program succeeds
Even when a program starts, the odds are stacked against it.
The mission. RINAE.AI was built to automate the system end to end — from genetic signal to a treated patient.
The Platform
Three tools. One surface.
Each stage is a real service the team ships today. The platform wires them into one automated, connected workflow with shared state, review gates, and an audit trail.
Admiral
Score amenability.
Multi-agent amenability scoring across modalities: specialist models weigh whether the target is treatable and produce a structured report.
- Signal
- Evidence
- Amenability
- Design
- Review
Metamorph
Design RNA medicines.
Generates antisense oligonucleotide and siRNA candidates with predictive efficacy and toxicity across many design parameters.
- Signal
- Evidence
- Amenability
- Design
- Review
HNRNPH2 · precision therapeutic triage (example)
IllustrativeExample workspace — illustrative, not a real analysis. The findings below are sample data, not a RINAE-produced result.
Guided OverviewStep 2 of 6
Intake
Evidence
Feasibility
Design
Review
Complete
Argus ◉ pulling evidence from 15 bioinformatics sources — ClinVar, gnomAD, GTEx, OMIM…
variantHNRNPH2:c.616C>T (p.Arg206Cys)
ClinVar · pathogenicexpressionHNRNPH2 brain-dominant
GTEx · 89.3 TPMconstraintpLI = 0.99 · LoF intolerant
gnomADargus · evidence graph
IllustrativePowered by highly connected, AI-ready databases.
Why we built this
“My daughter Rose was diagnosed with HNRNPH2 when she was three. We started RINAE to scale genetic medicines because Rose and millions of others couldn’t wait for the industry to care.”
CM
Casey McPherson
Founder · AlphaRose Therapeutics
Reference corpus
188K ASO patents
ASO Atlas: 417 distinct chemical designs distilled into Admiral's reasoning.
Why we exist
Built to make all genetic disease treatments economically possible.
One workflow
From genetic signal to a designed candidate — one connected workflow instead of fragmented, vendor-by-vendor handoffs.
AlphaRose Therapeutics
Request access to the tools.
Closed beta for Argus, Admiral, and Metamorph. Research use only.